Phase 2 Study of SR-8541A for Metastatic Colorectal Cancer
This study is testing a new combination of medicines, SR-8541A, botensilimab, and balstilimab, for people with metastatic colorectal cancer that is refractory (meaning it hasn't responded to other treatments) and is "microsatellite stable" (MSS-CRC). Researchers want to see how safe and effective this combination is, and to find the best dose. You may be able to join if you are 18 or older, have this type of colorectal cancer, and your tumor is not MSI-H/dMMR. The study will look at how well the treatment works and how your body tolerates it over cycles of 28 days.
- Study design
- This is a Phase 2 study, meaning it's an early-stage study to evaluate safety and effectiveness. It is an open-label study, so you and your doctors will know which treatments you are receiving. About 70 people are expected to participate.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary goals of the study are measured in 28-day cycles, but the total duration of follow-up is not specified.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
At a glance
Conditions
Where it's being run
6 sites across 3 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- To evaluate the safety, tolerability, efficacy, and define the optimal dose for expansion of SR-8541A in combination with botensilimab and balstilimabApproximately 3 dose levels (DL) will be investigated in 28-day cycles
Part 1 of the study is to establish the recommended dose of SR-8541A in combination with botensilimab and balstilimab.